• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

基于数据综合和生物信息学方法,miR-221 和 miR-222 作为甲状腺乳头状癌鉴别诊断中潜在底物的生物标志物价值。

Biomarker Value of miR-221 and miR-222 as Potential Substrates in the Differential Diagnosis of Papillary Thyroid Cancer Based on Data Synthesis and Bioinformatics Approach.

机构信息

Department of Radiotherapy & Oncology, The Second Affiliated Hospital of Soochow University, Suzhou, China.

Institute of Radiotherapy & Oncology, Soochow University, Suzhou, China.

出版信息

Front Endocrinol (Lausanne). 2022 Feb 7;12:794490. doi: 10.3389/fendo.2021.794490. eCollection 2021.

DOI:10.3389/fendo.2021.794490
PMID:35197926
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8859251/
Abstract

BACKGROUND

MicroRNA (miRNA) has been reported to play a critical regulatory role in papillary thyroid carcinomas (PTC). However, the role of miR-221/222 in PTC remains unclear. Here, we performed this study to explore the diagnostic potentials and mechanisms of miR-221/222 in PTC.

METHODS

First, we systematically analyzed the diagnostic value of miR-221/222 in the diagnosis PTC by pooling the published studies. Afterwards, we performed comprehensive bioinformatics analysis including gene ontology analysis, pathway enrichment analysis and protein-protein interaction analysis to explore the potential mechanisms of miR-221/222 involved in PTC.

RESULTS

The overall sensitivity and specificity of miR-221/222 for PTC were 0.75 (95% CI: 0.70-0.80) and 0.80 (95% CI: 0.76-0.84) respectively with the AUC of 0.85 (95% CI: 0.81-0.88). The diagnostic performance varied among different subgroups including geographical locations, sample sources and sample sizes. Meanwhile, we found that a combination of miR-221/222 and other miRNAs when used in a diagnostic panel could improve the diagnostic accuracy than individual miR-221/222. Moreover, through the bioinformatics analysis, we confirmed that miR-221/222 targets were highly related to the molecular pathogenesis of PTC. The results revealed that miR-221/222 may exert important functions in PTC through thyroid hormone signaling pathway and some other key pathways by regulating some key genes.

CONCLUSION

These findings indicated that miR-221/222 have the potential to serve as auxiliary tools for diagnosing PTC. Further prospective clinical trials should be performed to assess the accuracy of these findings in a larger cohort and determine the clinical uses.

摘要

背景

MicroRNA (miRNA) 已被报道在甲状腺乳头状癌 (PTC) 中发挥关键的调控作用。然而,miR-221/222 在 PTC 中的作用尚不清楚。在这里,我们进行了这项研究,以探讨 miR-221/222 在 PTC 中的诊断潜力和机制。

方法

首先,我们通过汇总已发表的研究系统地分析了 miR-221/222 在 PTC 诊断中的诊断价值。之后,我们进行了全面的生物信息学分析,包括基因本体分析、通路富集分析和蛋白质-蛋白质相互作用分析,以探讨 miR-221/222 参与 PTC 的潜在机制。

结果

miR-221/222 对 PTC 的总体敏感性和特异性分别为 0.75(95%CI: 0.70-0.80)和 0.80(95%CI: 0.76-0.84),AUC 为 0.85(95%CI: 0.81-0.88)。诊断性能在包括地理位置、样本来源和样本量在内的不同亚组中存在差异。同时,我们发现 miR-221/222 与其他 miRNAs 联合使用组成诊断面板可提高诊断准确性,优于单独使用 miR-221/222。此外,通过生物信息学分析,我们证实 miR-221/222 的靶基因与 PTC 的分子发病机制高度相关。结果表明,miR-221/222 可能通过甲状腺激素信号通路和其他一些关键途径,通过调节一些关键基因,在 PTC 中发挥重要作用。

结论

这些发现表明 miR-221/222 有可能成为辅助诊断 PTC 的工具。需要进一步进行前瞻性临床试验,以评估这些发现在更大队列中的准确性,并确定其临床用途。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c1d3/8859251/383d0a58a5a7/fendo-12-794490-g011.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c1d3/8859251/9b8ecf0680c6/fendo-12-794490-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c1d3/8859251/2882eb78cfe9/fendo-12-794490-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c1d3/8859251/aa9fac60cb89/fendo-12-794490-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c1d3/8859251/33a81097bc07/fendo-12-794490-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c1d3/8859251/db97c9e72b8d/fendo-12-794490-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c1d3/8859251/3e2143357194/fendo-12-794490-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c1d3/8859251/c34d9bbe526b/fendo-12-794490-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c1d3/8859251/06cc67de620f/fendo-12-794490-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c1d3/8859251/171a85f92b09/fendo-12-794490-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c1d3/8859251/92ad3d5a6c06/fendo-12-794490-g010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c1d3/8859251/383d0a58a5a7/fendo-12-794490-g011.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c1d3/8859251/9b8ecf0680c6/fendo-12-794490-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c1d3/8859251/2882eb78cfe9/fendo-12-794490-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c1d3/8859251/aa9fac60cb89/fendo-12-794490-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c1d3/8859251/33a81097bc07/fendo-12-794490-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c1d3/8859251/db97c9e72b8d/fendo-12-794490-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c1d3/8859251/3e2143357194/fendo-12-794490-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c1d3/8859251/c34d9bbe526b/fendo-12-794490-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c1d3/8859251/06cc67de620f/fendo-12-794490-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c1d3/8859251/171a85f92b09/fendo-12-794490-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c1d3/8859251/92ad3d5a6c06/fendo-12-794490-g010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c1d3/8859251/383d0a58a5a7/fendo-12-794490-g011.jpg

相似文献

1
Biomarker Value of miR-221 and miR-222 as Potential Substrates in the Differential Diagnosis of Papillary Thyroid Cancer Based on Data Synthesis and Bioinformatics Approach.基于数据综合和生物信息学方法,miR-221 和 miR-222 作为甲状腺乳头状癌鉴别诊断中潜在底物的生物标志物价值。
Front Endocrinol (Lausanne). 2022 Feb 7;12:794490. doi: 10.3389/fendo.2021.794490. eCollection 2021.
2
BCL2 and hsa-miR-181a-5p are potential biomarkers associated with papillary thyroid cancer based on bioinformatics analysis.基于生物信息学分析,BCL2 和 hsa-miR-181a-5p 是与甲状腺乳头状癌相关的潜在生物标志物。
World J Surg Oncol. 2019 Dec 16;17(1):221. doi: 10.1186/s12957-019-1755-9.
3
MicroRNA-222 Promotes Invasion and Metastasis of Papillary Thyroid Cancer Through Targeting Protein Phosphatase 2 Regulatory Subunit B Alpha Expression.微小 RNA-222 通过靶向蛋白磷酸酶 2 调节亚基 Bα表达促进甲状腺乳头状癌的侵袭和转移。
Thyroid. 2018 Sep;28(9):1162-1173. doi: 10.1089/thy.2017.0665. Epub 2018 Aug 21.
4
Cyto-Histological Profile of MicroRNAs as Diagnostic Biomarkers in Differentiated Thyroid Carcinomas.细胞组织学特征分析 miRNA 在分化型甲状腺癌中的诊断生物标志物。
Genes (Basel). 2024 Mar 21;15(3):389. doi: 10.3390/genes15030389.
5
Aberrant expression of five miRNAs in papillary thyroid carcinomas.五种微小 RNA 在甲状腺乳头状癌中的异常表达。
J Clin Lab Anal. 2021 Sep;35(9):e23907. doi: 10.1002/jcla.23907. Epub 2021 Jul 16.
6
miR-1301-3p suppresses tumor growth by downregulating PCNA in thyroid papillary cancer.miR-1301-3p 通过下调甲状腺乳头状癌中的 PCNA 抑制肿瘤生长。
Am J Otolaryngol. 2021 Mar-Apr;42(2):102920. doi: 10.1016/j.amjoto.2021.102920. Epub 2021 Jan 9.
7
A potential biomarker hsa-miR-200a-5p distinguishing between benign thyroid tumors with papillary hyperplasia and papillary thyroid carcinoma.一种潜在的生物标志物 hsa-miR-200a-5p,可区分具有乳头状增生的良性甲状腺肿瘤和甲状腺乳头状癌。
PLoS One. 2018 Jul 13;13(7):e0200290. doi: 10.1371/journal.pone.0200290. eCollection 2018.
8
A three-microRNA panel in serum as novel biomarker for papillary thyroid carcinoma diagnosis.血清中的一个三微小RNA组合作为乳头状甲状腺癌诊断的新型生物标志物。
Chin Med J (Engl). 2020 Nov 5;133(21):2543-2551. doi: 10.1097/CM9.0000000000001107.
9
Identification of Prognostic Biomarkers in Papillary Thyroid Cancer and Developing Non-Invasive Diagnostic Models Through Integrated Bioinformatics Analysis.通过整合生物信息学分析鉴定甲状腺乳头状癌的预后生物标志物并建立非侵入性诊断模型。
Microrna. 2022;11(1):73-87. doi: 10.2174/2211536611666220124115445.
10
Expression Levels of MicroRNA-300/BCL2L11 in Papillary Thyroid Cancer and Their Clinical Diagnostic Values.微小RNA-300/BCL2L11在甲状腺乳头状癌中的表达水平及其临床诊断价值
Eur Surg Res. 2023;64(3):342-351. doi: 10.1159/000530682. Epub 2023 May 15.

引用本文的文献

1
Preoperative Expression Profiles of miR-146a and miR-221 as Potential Biomarkers for Differentiating Benign from Malignant Thyroid Nodules.miR-146a和miR-221的术前表达谱作为鉴别甲状腺良恶性结节的潜在生物标志物
Int J Mol Sci. 2025 Aug 5;26(15):7564. doi: 10.3390/ijms26157564.
2
Evaluating the performance of multi-omics integration: a thyroid toxicity case study.评估多组学整合的性能:一项甲状腺毒性案例研究。
Arch Toxicol. 2025 Jan;99(1):309-332. doi: 10.1007/s00204-024-03876-2. Epub 2024 Oct 23.
3
The Application of microRNAs in Papillary Thyroid Cancer: A Bibliometric and Visualized Analysis.

本文引用的文献

1
miR-30b-5p inhibits proliferation, invasion, and migration of papillary thyroid cancer by targeting GALNT7 via the EGFR/PI3K/AKT pathway.微小RNA-30b-5p通过表皮生长因子受体/磷脂酰肌醇-3-激酶/蛋白激酶B信号通路靶向多肽N-乙酰半乳糖胺基转移酶7,抑制甲状腺乳头状癌的增殖、侵袭和迁移。
Cancer Cell Int. 2021 Nov 24;21(1):618. doi: 10.1186/s12935-021-02323-x.
2
Prognostic and Immune-Infiltrate Significance of miR-222-3p and Its Target Genes in Thyroid Cancer.miR-222-3p及其靶基因在甲状腺癌中的预后及免疫浸润意义
Front Genet. 2021 Oct 19;12:710412. doi: 10.3389/fgene.2021.710412. eCollection 2021.
3
Long Noncoding RNA GAS5 Targeting miR-221-3p/Cyclin-Dependent Kinase Inhibitor 2B Axis Regulates Follicular Thyroid Carcinoma Cell Cycle and Proliferation.
微小RNA在甲状腺乳头状癌中的应用:文献计量学与可视化分析
Int J Gen Med. 2024 Oct 15;17:4681-4699. doi: 10.2147/IJGM.S487239. eCollection 2024.
4
MiRNAs in Extracellular Vesicles as Biomarkers in Plasma of Papillary Thyroid Cancer Patients: A Proof-of-Concept Study.甲状腺乳头状癌患者血浆中细胞外囊泡内的微小RNA作为生物标志物:一项概念验证研究。
Biology (Basel). 2024 Sep 22;13(9):743. doi: 10.3390/biology13090743.
5
Novel role of lncRNAs regulatory network in papillary thyroid cancer.长链非编码RNA调控网络在甲状腺乳头状癌中的新作用
Biochem Biophys Rep. 2024 Feb 29;38:101674. doi: 10.1016/j.bbrep.2024.101674. eCollection 2024 Jul.
6
Effective Use of microRNA, BRAF and Sonographic Risk Assessment in Bethesda III Thyroid Nodules Requires a Different Approach to Nodules with Features of Nuclear Atypia and Other Types of Atypia.在贝塞斯达Ⅲ类甲状腺结节中有效利用微小RNA、BRAF和超声风险评估,对于具有核异型性特征和其他异型性类型的结节需要采用不同的方法。
Cancers (Basel). 2023 Aug 27;15(17):4287. doi: 10.3390/cancers15174287.
7
New biomarkers: prospect for diagnosis and monitoring of thyroid disease.新生物标志物:甲状腺疾病的诊断和监测前景。
Front Endocrinol (Lausanne). 2023 Jul 21;14:1218320. doi: 10.3389/fendo.2023.1218320. eCollection 2023.
8
The clinical implications of circulating microRNAs as potential biomarkers in screening oral squamous cell carcinoma.循环微小RNA作为口腔鳞状细胞癌筛查潜在生物标志物的临床意义
Front Oncol. 2022 Nov 17;12:965357. doi: 10.3389/fonc.2022.965357. eCollection 2022.
9
Thyroid Cancer Persistence in Patients with Unreliable Thyroglobulin Measurement: Circulating microRNA as Candidate Alternative Biomarkers.甲状腺球蛋白测量不可靠患者的甲状腺癌持续存在:循环微小RNA作为候选替代生物标志物
Cancers (Basel). 2022 Nov 16;14(22):5620. doi: 10.3390/cancers14225620.
10
Expression Profile and Diagnostic Significance of MicroRNAs in Papillary Thyroid Cancer.微小RNA在甲状腺乳头状癌中的表达谱及诊断意义
Cancers (Basel). 2022 May 28;14(11):2679. doi: 10.3390/cancers14112679.
长链非编码 RNA GAS5 通过靶向 miR-221-3p/细胞周期蛋白依赖性激酶抑制剂 2B 轴调控滤泡状甲状腺癌细胞周期和增殖。
Pathobiology. 2021;88(4):289-300. doi: 10.1159/000513338. Epub 2021 Jun 15.
4
miR-221-3p and miR-222-3p regulate the SOCS3/STAT3 signaling pathway to downregulate the expression of NIS and reduce radiosensitivity in thyroid cancer.miR-221-3p和miR-222-3p调节SOCS3/STAT3信号通路,以下调甲状腺癌中NIS的表达并降低放射敏感性。
Exp Ther Med. 2021 Jun;21(6):652. doi: 10.3892/etm.2021.10084. Epub 2021 Apr 19.
5
Long Noncoding RNAs at the Crossroads of Cell Cycle and Genome Integrity.长非编码 RNA 在细胞周期和基因组完整性的交汇处。
Trends Genet. 2021 Jun;37(6):528-546. doi: 10.1016/j.tig.2021.01.006. Epub 2021 Mar 5.
6
Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.《全球癌症统计数据 2020:全球 185 个国家和地区 36 种癌症的发病率和死亡率估计》。
CA Cancer J Clin. 2021 May;71(3):209-249. doi: 10.3322/caac.21660. Epub 2021 Feb 4.
7
Bringing MicroRNAs to Light: Methods for MicroRNA Quantification and Visualization in Live Cells.揭示微小RNA:活细胞中微小RNA定量与可视化方法
Front Bioeng Biotechnol. 2021 Jan 18;8:619583. doi: 10.3389/fbioe.2020.619583. eCollection 2020.
8
Syndecan-1 and stromal heparan sulfate proteoglycans: key moderators of plasma cell biology and myeloma pathogenesis.Syndecan-1 和基质肝素硫酸蛋白聚糖:浆细胞生物学和骨髓瘤发病机制的关键调节物。
Blood. 2021 Apr 1;137(13):1713-1718. doi: 10.1182/blood.2020008188.
9
The Gene Ontology resource: enriching a GOld mine.基因本体论资源:丰富一个 GOld 矿。
Nucleic Acids Res. 2021 Jan 8;49(D1):D325-D334. doi: 10.1093/nar/gkaa1113.
10
Regulation of Hippo signaling pathway in cancer: A MicroRNA perspective.Hippo 信号通路在癌症中的调控:miRNA 的视角
Cell Signal. 2021 Feb;78:109858. doi: 10.1016/j.cellsig.2020.109858. Epub 2020 Nov 27.